Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
September 27 2021 - 7:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2021.
____________________
Commission File Number: 001-39071
ADC Therapeutics SA
(Exact name of registrant as specified in its
charter)
Biopôle
Route
de la Corniche 3B
1066
Epalinges
Switzerland
(Address
of principal executive office)
Indicate by check
mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
ADC Therapeutics
Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
ADCT-901 targets
KAAG1, a novel tumor target for ADC development
LAUSANNE, Switzerland,
September 27, 2021 – ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those
affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and
solid tumors, today announced the first patient has been dosed in the Phase 1 clinical trial evaluating ADCT-901, targeting kidney associated
antigen 1 (KAAG1), in patients with selected advanced solid tumors with high unmet medical needs.
ADCT-901 is composed
of a humanized monoclonal antibody (3A4) directed against human KAAG1 conjugated through a cathepsin-cleavable linker to the PBD dimer
SG3199, the same cytotoxin used in ADCT’s lead product, ZYNLONTA®. KAAG1 is an attractive,
novel tumor target for ADCs expressed on the membrane of tumor cells, while its expression on healthy tissue is very limited.
The open-label,
dose-escalation and dose-expansion clinical trial will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-901 as
monotherapy in patients with selected advanced solid tumors. For more information about the Phase 1 trial, please visit www.clinicaltrials.gov
(identifier NCT04972981).
About ADC Therapeutics
ADC Therapeutics
(NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted
antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm
for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’
CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment
of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory
Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics
has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics
is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.
ZYNLONTA® is a registered trademark
of ADC Therapeutics SA.
INCORPORATION
BY REFERENCE
This Report on Form
6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-256686 and 333-256807)
of ADC Therapeutics SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents
or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
ADC Therapeutics SA
|
Date: September 27, 2021
|
|
|
|
|
By:
|
/s/ Michael Forer
|
|
Name:
|
Michael Forer
|
|
Title:
|
Executive Vice President and General Counsel
|
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Sep 2023 to Sep 2024